StemCyte Introduces Insurance-Linked Cord Blood Access in Taiwan

StemCyte International, an AABB-accredited organization, launched a new program in Taiwan that connects insurance coverage to public cord blood access for blood stem cell transplant. Developed in partnership with Taishin Life, StemCyte’s public bank matching protection service enables policyholders to receive immediate support for cell therapy through the organization’s dual public-private cord blood bank.

The initiative links insurance benefits directly to the availability of Regenecyte (HPC, Cord Blood), which received Food and Drug Administration approval in 2024 for unrelated allogeneic transplantation. StemCyte said this collaboration could serve as a model for future partnerships in the United States and other regions to expand access to cell therapy through insurance-backed programs.